Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Marin

Showing results (71-80 of 179) with videos related to

Pageof 18
Sort By:
Transplantation and Cellular Therapy|March 29, 2023
Impact of Donor Age in Haploidentical-Post-Transplantation Cyclophosphamide versus Matched Unrelated Donor Post-Transplantation Cyclophosphamide Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid LeukemiaRohtesh S Mehta, Jeremy Ramdial, David Marin, et al.
British Journal of Haematology|November 5, 2011
Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare systemHolger W Auner, Jiri Pavlu, Richard Szydlo, et al.
Journal of Cardiovascular Electrophysiology|March 16, 2013
Left atrial sphericity: a new method to assess atrial remodeling. Impact on the outcome of atrial fibrillation ablationFelipe Bisbal, Esther Guiu, Naiara Calvo, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 15, 2025
Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic LeukemiaNatalie Rafaeli, David Marin Costa, Celina Ledesma, et al.
Haematologica|March 26, 2003
Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progressionSarah Marktel, David Marin, Nicola Foot, et al.
American Journal of Hematology|January 11, 2012
BCR-ABL1 kinase domain mutations: methodology and clinical evaluationMary Alikian, Gareth Gerrard, Papagudi G Subramanian, et al.
The American Journal of Gastroenterology|October 29, 2024
Ulcerative Jejunitis in Celiac Disease: A 30-Year US ExperienceYevgen Chornenkyy, Masa Peric, David Marin Flores, et al.
Haematologica|April 21, 2009
The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinibJamshid Sorouri Khorashad, Simon Wagner, Liat Greener, et al.
Blood|September 14, 2010
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapyAmr R Ibrahim, Christos Paliompeis, Marco Bua, et al.
Haematologica|July 24, 2025
Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single centerBetül Oran, Peter Thall, Amin Alousi, et al.
Pageof 18

Showing results (71-80 of 179) with videos related to

Sort By:
Pageof 18
Transplantation and Cellular Therapy|March 29, 2023
Impact of Donor Age in Haploidentical-Post-Transplantation Cyclophosphamide versus Matched Unrelated Donor Post-Transplantation Cyclophosphamide Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid LeukemiaRohtesh S Mehta, Jeremy Ramdial, David Marin, et al.
British Journal of Haematology|November 5, 2011
Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare systemHolger W Auner, Jiri Pavlu, Richard Szydlo, et al.
Journal of Cardiovascular Electrophysiology|March 16, 2013
Left atrial sphericity: a new method to assess atrial remodeling. Impact on the outcome of atrial fibrillation ablationFelipe Bisbal, Esther Guiu, Naiara Calvo, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 15, 2025
Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic LeukemiaNatalie Rafaeli, David Marin Costa, Celina Ledesma, et al.
Haematologica|March 26, 2003
Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progressionSarah Marktel, David Marin, Nicola Foot, et al.
American Journal of Hematology|January 11, 2012
BCR-ABL1 kinase domain mutations: methodology and clinical evaluationMary Alikian, Gareth Gerrard, Papagudi G Subramanian, et al.
The American Journal of Gastroenterology|October 29, 2024
Ulcerative Jejunitis in Celiac Disease: A 30-Year US ExperienceYevgen Chornenkyy, Masa Peric, David Marin Flores, et al.
Haematologica|April 21, 2009
The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinibJamshid Sorouri Khorashad, Simon Wagner, Liat Greener, et al.
Blood|September 14, 2010
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapyAmr R Ibrahim, Christos Paliompeis, Marco Bua, et al.
Haematologica|July 24, 2025
Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single centerBetül Oran, Peter Thall, Amin Alousi, et al.
Pageof 18